Severe thrombocytopenia as a predictor of survival and response to hypomethylating agents: data from a Latin-American cohort

LAZZARINO, CAROLINA; IASTREBNER, MARCELO; GONZALEZ, JACQUELINE; ARBELBIDE, JORGE; BASQUIERA, ANA L; CRISP, RENÉE; ESPINOSA, DANIEL; KORNBLIHTT, LAURA; MACCHIAVELLO, E; PERESSIN, R; PINTOS, NOEMÍ; BENGIÓ, RAQUEL; RIVAS, M MARTA; ROSENHAIN, MARIANA; GUSMAO, BRENO; PRATES, M VIRGINIA; BELLI, CAROLINA

Estocolmo

Congreso; 23rd Congress of the European Hematology Association; 2018

European Hematology Association

Background: Hypomethylating agents (HMA) are the first line option for high-risk patient and lower-risk patient with transfusiondependence, or, during the follow-up according to worsening clinical features. Thrombocytopenia is a frequent finding inmyelodysplastic syndromes (MDS) during the course of the disease and, recently, severe thrombocytopenia (